Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Downgrades Veracyte to Market Perform

Raymond James Downgrades Veracyte to Market Perform

Raymond James analyst Andrew Cooper downgrades Veracyte (NASDAQ:VCYT) from Outperform to Market Perform.

byBenzinga Newsdesk

January 18, 2023

1 minute read

Raymond James analyst Andrew Cooper downgrades Veracyte (NASDAQ:VCYT) from Outperform to Market Perform.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today

By Benzinga Insights

July 10, 4:00 PM

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 15 years by 8.58% on an annualized basis…

ISRG

News

Apollo Boosts Presence in Europe With New, Expanded London Office

By Benzinga Newsdesk

April 17, 4:11 AM

Apollo (NYSE:APO) today announced the opening of a new office in London, United Kingdom, strengthening its presence in Europe and building on the firm's successful track record in the region. The transition to a

APO

Analyst Ratings

Analyst Expectations For Stoke Therapeutics’s Future

By Benzinga Insights

May 6, 11:01 AM

Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from…

STOK

Wix.com Q3 EPS $0.06 Beats $(0.09) Estimate, Sales $305.81M Miss $343.33M Estimate

By Benzinga Newsdesk

November 10, 2:44 AM

Wix.com (NASDAQ:WIX) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.09) by 166.67 percent. This is a 128.57 percent increase over losses of $(0.21) per share from the same

WIX

Raymond James Downgrades Veracyte to Market Perform

Related Posts

$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today

Apollo Boosts Presence in Europe With New, Expanded London Office

Analyst Expectations For Stoke Therapeutics’s Future

Wix.com Q3 EPS $0.06 Beats $(0.09) Estimate, Sales $305.81M Miss $343.33M Estimate